NewsCura

Monde Nissin Corporation

Disclaimer: The research and recommendation below were generated by Claude Fable. Please treat this as one input for your own research — not as the sole basis for any decision to buy or sell a stock.

Last checked
Price
6.8200
Trading status
Normal
Recommendation
Hold (solid domestic core; Quorn recovery unproven)Hold
Committee call
Buy
Indices
PSEi

Analysis

MONDE - Monde Nissin Corporation

One-line summary: A strong, growing Philippine noodle-and-snacks franchise is finally offsetting a UK meat-alternative unit that has destroyed over P35 billion in cumulative impairments since the 2021 IPO, and the stock still trades near half its P13.50 offer price.

Snapshot
Reviewed July 19, 2026
Index membership PSEi
Price at review P6.82 (July 17, 2026 close; 52-week range P5.61-P7.96)
Recommendation Hold (core business is healthy and cheap; Quorn recovery is real but not yet proven durable)
Market cap P122.5B (17.97B shares)
Trailing P/E ~12.8x
Estimated forward P/E (2026) ~11.7x (core profit growing low double digits)
Dividend P0.24/share latest declaration (ex April 23, 2026; paid May 21, 2026), trailing yield ~5.9-7.0% depending on annualization
P/B ~2.07x
Debt Low and falling (D/E ~0.08)

Two businesses in one stock

Monde Nissin is really two companies bolted together by one 2021 IPO. The Asia-Pacific Branded Food and Beverage (APAC BFB) division, Lucky Me! instant noodles, SkyFlakes and Fita biscuits, and assorted beverages and culinary aids across the Philippines, Indonesia, and other APAC markets, is the cash engine: net sales of P72.8B in 2025 (up 4.7%), with domestic sales up 5.4% and volumes growing across every category. Q1 2026 kept the streak going: consolidated revenue up 9.1% to P22.8B, APAC BFB net sales up 8.6% to P19.1B, domestic sales up 9.5% (international sales actually fell 5.1%, so the growth is a Philippine and near-region story, not a global one).

The second business is Marlow Foods, the UK maker of Quorn and Cauldron mycoprotein products, acquired in 2015 and central to Monde Nissin's IPO pitch as a global plant-based growth story. It has instead been the single biggest destroyer of shareholder capital in the stock's history: revenue at Marlow Foods slid from £220M in 2021 to £204.9M in 2023 as UK and US demand for meat alternatives cooled sharply, and the unit has taken large impairment charges every year from 2022 through 2024 (roughly P20.5B in 2022, ~£145M, roughly P9-10B, in 2023, and a further £80-100M flagged for 2024). Full year 2025 was the first year without a fresh impairment: the unit posted a modest reversal of prior impairment losses, gross margin expanded over 500 basis points, and bottom-line losses narrowed to P304M after tax from P804M in 2024. Q1 2026 continued the improvement: Quorn revenue was up 1.4% on a constant-currency basis (11.7% reported, helped by currency), gross margin expanded 881 basis points to 31.8%, and core EBITDA rose to P325M from P140M a year earlier. The trend is genuinely better. It is not yet a profitable business on a full-year basis, and "less bad" after three years of billions in writedowns is a low bar.

Revenue and earnings: a wild five-year ride

Consolidated revenue: P69.3B (2021), P73.9B (2022), P80.2B (2023), P83.1B (2024), P86.5B (2025); trailing twelve months (through Q1 2026) P88.4B. Growth has been steady and mostly domestic-driven throughout, even in the years the bottom line was a disaster.

Reported net income tells the impairment story: P3.1B (2021), a loss of P13.0B (2022, dominated by the first big Quorn writedown), a loss of P0.6B (2023, another writedown), P0.4B (2024, still near breakeven), P8.6B (2025, first clean year with an impairment reversal rather than a charge). TTM net income through Q1 2026 is P9.6B. Core net income, the company's own measure that strips out impairments and one-off items, has been more stable: P9.7B for full-year 2025 (down 0.8%), and P3.3B in Q1 2026 (up 11% year on year, with reported net income up 34% thanks to foreign-exchange gains and fair value adjustments). Read the reported net income line with caution: three of the last five years were shaped almost entirely by non-cash Quorn impairments and reversals, not by the underlying operating business.

Dividend sustainability: young and growing, but short history

Monde Nissin only became a consistent, growing dividend payer once the Quorn losses stopped swallowing the entire earnings base. Per-share declarations: P0.12 (May 2024), P0.14 (November 2024), P0.15 (April 2025), P0.16 (December 2025), P0.24 (April 2026, paid May 21, 2026). That is four consecutive increases and a near-doubling in two years, which is encouraging, but the dividend was effectively non-existent or erratic in 2022-2023 while the company was absorbing impairment losses (cash dividends paid per the cash flow statement: P10.1B in 2021, P2.5B in 2022, nothing recorded in 2023, P6.8B in 2024, P2.7B in 2025; the swings reflect both special payouts and payment-timing lags against the per-share declaration dates above). StockAnalysis.com puts the payout ratio around 58% of trailing earnings and the trailing yield around 6.8% on an annualized basis; on the actual trailing 12-month cash payments (P0.16 + P0.24 = P0.40) the yield is closer to 5.7%. Either way it's a real and growing yield, but the payment history is only two to three years deep, not the multi-decade record URC or the banks can point to.

ROE: whipsawed by Quorn, now clean

ROE has moved from mediocre to catastrophic to strong purely on the back of Quorn impairments: 6.8% (2021), -21.6% (2022), -1.1% (2023), 0.8% (2024), 14.9% (2025), 16.6% trailing. Debt is low throughout (D/E fell from 0.24 in 2022 to 0.08 currently), so none of the current 16.6% ROE is leverage-flattered; it reflects a genuinely profitable core business now that the impairment drag has stopped. The open question is whether 2025's ROE holds if Quorn ever needs another writedown, which has happened in three of the last four years.

Free cash flow: consistently positive through the whole mess

Unlike the earnings line, free cash flow never went deeply negative, which says the core APAC BFB business kept throwing off cash even while Quorn's balance sheet value was being written down. Operating cash flow: P13.5B (2021), P5.5B (2022), P13.3B (2023), P13.0B (2024), P11.3B (2025). Capex has run P3.6B-P5.2B a year with no major expansion binge. Free cash flow: P8.3B (2021), P1.1B (2022, the weakest year), P9.7B (2023), P8.2B (2024), P6.6B (2025). This is the strongest argument for the stock: even during the years the reported P&L showed a net loss, the business was cash generative enough to fund capex and pay some dividend.

Capital allocation and governance: an unusual backstop

Ownership is concentrated: Indonesian tycoon Hartono Kweefanus (chairman) holds roughly 23%, his brother and vice chairman Hoediono roughly 5.3%, and Hoediono's wife Betty Ang (president) roughly 18%, with the family group controlling close to 70% of the company. In November 2023, after the Quorn impairments had wiped out roughly P60B of market value, CEO Henry Soesanto and the controlling family shareholders agreed to personally backstop future impairment losses at the Quorn-holding subsidiary for ten years (FY2023 through FY2032), capped at 12% of Monde Nissin's outstanding shares, with a one-time settlement payable by June 2033. It's a genuinely unusual arrangement (insiders putting personal wealth behind a specific loss-making unit) and it can be read two ways: as a credible signal that the family won't let Quorn sink the parent, or as an admission of how badly that acquisition has gone. There's no meaningful buyback program; capital has gone into servicing the core APAC business and absorbing the meat-alternative losses rather than into shrinking the share count.

IPO price P13.50: the overhang that hasn't gone away

Monde Nissin priced its IPO at P13.50 in May 2021, the largest IPO in PSE history, raising P48.6B and valuing the company at roughly P242B. It closed its debut day at P13.48, essentially flat, and has been a disappointment ever since: down as much as 50% from its all-time high of P19.92 (September 2021) at various points, and still down roughly 48% from the offer price at the current P7.01. Market cap today is roughly P125B, about half the IPO valuation. Anyone who bought the IPO on the strength of the Quorn growth story has lost half their capital even as the domestic noodle-and-snacks business has grown steadily every year since; the entire value destruction traces to one overseas acquisition and its repeated writedowns.

Verdict at P6.82 (July 19, 2026)

Hold, unchanged from the July 12, 2026 review. No material news has landed in the week since: the only corporate disclosure was a routine, compulsory-retirement-age exit of the Chief Information and Digital Officer (effective July 1, 2026), not a fundamentals event. No fresh impairment, no new dividend declaration, no index change, and the next earnings release (Q2 2026) is now about three weeks out, due August 12, 2026. Neither buy trigger nor sell trigger has fired. The stock has drifted down from P6.98 to P6.82, pulling the trailing P/E to ~12.8x and the dividend yield to roughly 6-7%, marginally cheaper than a week ago on an unchanged story. The APAC branded foods business is a legitimately good, growing, cash-generative franchise trading at a reasonable multiple with low debt and a rising dividend. That alone would make the stock attractive. But this is not a clean single-business story: Quorn has taken impairments in three of the last four years, only just turned in a full year without a fresh writedown, and remains a single-digit-margin recovery story rather than a proven earner. The controlling family's decision to personally backstop future Quorn losses through 2032 tells you management itself isn't fully confident the segment is fixed. At P6.82 the market is pricing in continued domestic growth plus a Quorn unit that stops being a drag; that's a reasonable base case given the 2025-2026 trend, not a bargain that prices in further deterioration. This isn't a stock to chase at these levels, but it's not one to avoid either if you already hold it.

What would change the call:

  • Buy trigger: Quorn/meat-alternative segment posts a full fiscal year of net profit (not just a narrowing loss or a one-off impairment reversal), confirming the 2025-2026 recovery is durable; or the price falls toward book value (roughly P3.30/share given the current ~2.1x P/B) without new negative news on the core APAC business.
  • Sell trigger (if owned): a fresh material impairment at Quorn signaling the 2025 reversal was premature, a cut to the now four-times-raised dividend, or the family-backstop arrangement being renegotiated or abandoned in a way that suggests deeper problems.

Analysis, not financial advice.

Committee review (July 19, 2026)

Five investor lenses judged this page's facts independently, each strictly inside its own framework, with no cross-talk between them.

Lens Signal Confidence Core argument
Ben Graham Bearish 68 Two net losses in the review period (P13.0B in 2022, P0.6B in 2023) fail his ten-year no-deficit test regardless of the 2025 recovery to P8.6B; financing is genuinely conservative (D/E 0.08), but P/E (12.8x) times P/B (2.07x) is roughly 26.5, still above his 22.5 ceiling, and the dividend record (started 2024) is too short to count as a sustained payout history.
Warren Buffett Bullish 62 Lucky Me!/SkyFlakes give APAC F&B a real, durable moat, and free cash flow stayed positive every single year (P8.3B down to P1.1B and back to P9.7B, P8.2B, P6.6B) even through the impairment years, proving owner-earnings power independent of accounting noise; D/E of 0.08 means the 16.58% trailing ROE is real, not leverage-manufactured, and the family's personal backstop on Quorn losses through 2033 is skin-in-the-game alignment, though only two years of clean ROE isn't yet the decade of proof his framework wants.
Michael Burry Bullish 62 Strip out the non-cash Quorn impairments and five straight years of positive free cash flow (P8.3B to P6.6B) coexisted with a P20.5B and P9-10B non-cash writedown and a P13.0B reported loss in 2022, meaning GAAP understated the cash reality; market cap (~P122.5B) is still half the IPO valuation, pricing in permanent Marlow damage that the family's 10-year impairment backstop now caps, and the Q1 2026 "34-35% growth" headline is FX noise, not the real 11% core growth number.
Nassim Taleb Neutral 50 The 2022 Marlow covenant breach and three straight years of impairments already crystallized the tail risk, and D/E down to 0.08 with FCF positive even in the loss year shows the balance sheet no longer carries fragile refinancing exposure; the lasting flaw is payoff asymmetry, the family collected P48.6B at IPO before ~P60B of value was wiped out, and their backstop is capped at 12% of shares with settlement deferred to 2033.
Stanley Druckenmiller Bullish 58 The catalyst is the August 12, 2026 print, three weeks out, against core net income already growing (P3.3B Q1, +11%) and Marlow's turnaround compounding (gross margin +881bps, EBITDA more than doubled); payoff is asymmetric, four straight dividend hikes and 0.08x D/E cap the downside near the 52-week low (P5.61), while a clean Marlow quarter could push toward the ~P8.79 analyst target, a ~29% move against limited balance-sheet risk.

Conferred call: Buy (3 bullish, 1 bearish, 1 neutral). This disagrees with the page's Hold recommendation, which the SOP says to keep rather than soften: no buy trigger has actually fired (Quorn hasn't posted a full profitable fiscal year, and the price hasn't fallen to book value), so the page stays Hold while noting the committee leans more bullish than the page's own bar for upgrading. No conflict with Brain/concepts/stock-trading-strategy-and-rules.md: there is a real catalyst (the August 12 print) rather than a "cheap at the lows" trap, and three of five lenses see the setup as clean enough to act on, even though the page's own explicit triggers haven't cleared yet.

Shared flip trigger: four of the five lenses (Buffett, Burry, Taleb, Druckenmiller) converge on the same threshold, a fresh Marlow/Quorn impairment or a reversion to loss at the August 12 print would flip them bearish, while continued absence of a writedown through the next one to two quarters is what would make the bulls' case durable.

Review history

Date Price Recommendation
July 10, 2026 7.01 Hold (strong domestic core, Quorn recovery unproven, still ~48% below IPO price)
July 12, 2026 6.98 Hold (no material change since July 10; committee split 2 bullish/2 bearish/1 neutral, conferred Hold)
July 19, 2026 6.82 Hold (no material news beyond a routine executive retirement; neither trigger fired; committee flipped to 3 bullish/1 bearish/1 neutral, conferred Buy, disagreeing with the page's Hold)

Sources